Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Application of Erythropoietin in Chronic Heart Failure Treatment

Author(s): Atena Pourtaji, Vajiheh Jahani, Amirhossein Sahebkar*, Thozhukat Sathyapalan and Amir Hooshang Mohammadpour*

Volume 20, Issue 20, 2020

Page: [2080 - 2089] Pages: 10

DOI: 10.2174/1389557520999200728155543

Price: $65

Abstract

Heart Failure (HF) is recognized as an important public health concern worldwide, especially in developed countries, due to its high rate of morbidity and mortality. Although new pharmacological and non-pharmacological agents have improved the clinical sequelae of HF in patients, its mortality remains high, especially among the elderly. Erythropoietin (EPO), a glycoprotein, besides its traditional role in promoting erythropoiesis and production of erythroid progenitors, its beneficial role in reducing infarct area and improving heart function through EPO-induced antiapoptotic and antioxidant effects have been increasingly recognized. This review gathers the evidence to date about the effectiveness of EPO in HF patients. In addition to the growing evidence of EPO in the treatment of HF in the animal studies for improving cardiac function and infarct size, more clinical studies are needed to assess the role of EPO treatment in the management of HF.

Keywords: Congestive heart failure, erythropoietin, clinical trial, endothelial precursor cell, ROS, AMPK.

« Previous Next »
Graphical Abstract

[1]
De Boer, RA; Pinto, YM; Van Veldhuisen, DJ The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: The role of microvascular growth and abnormalities. Microcirculation (New York, NY: 1994)., 2003, 10(2), 113-126.
[http://dx.doi.org/10.1080/713773607]
[2]
McMurray, J.J.; Petrie, M.C.; Murdoch, D.R.; Davie, A.P. Clinical epidemiology of heart failure: Public and private health burden. Eur. Heart J., 1998, 19(Suppl. 1), 9-16.
[PMID: 9886707]
[3]
Maiese, K.; Li, F.; Chong, Z.Z. New avenues of exploration for erythropoietin. JAMA, 2005, 293(1), 90-95.
[http://dx.doi.org/10.1001/jama.293.1.90] [PMID: 15632341]
[4]
van der Meer, P.; Voors, A.A.; Lipsic, E.; van Gilst, W.H.; van Veldhuisen, D.J. Erythropoietin in cardiovascular diseases. Eur. Heart J., 2004, 25(4), 285-291.
[http://dx.doi.org/10.1016/j.ehj.2003.11.017] [PMID: 14984916]
[5]
van der Meer, P.; Lipsic, E. Erythropoietin: Repair of the failing heart. J. Am. Coll. Cardiol., 2006, 48(1), 185-186.
[http://dx.doi.org/10.1016/j.jacc.2006.04.007 ] [PMID: 16814665]
[6]
Rossert, J.; Eckardt, K-U. Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol. Dial. Transplant., 2005, 20(6), 1025-1028.
[http://dx.doi.org/10.1093/ndt/gfh800] [PMID: 15840686]
[7]
Mastromarino, V; Volpe, M; Musumeci, MB; Autore, C; Conti, E Erythropoietin and the heart: Facts and perspectives. Clinical science (London, England: 1979)., 2011, 120(2), 51-63.
[http://dx.doi.org/10.1042/CS20100305]
[8]
Henry, D.H.; Bowers, P.; Romano, M.T.; Provenzano, R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch. Intern. Med., 2004, 164(3), 262-276.
[http://dx.doi.org/10.1001/archinte.164.3.262] [PMID: 14769622]
[9]
Hirata, A.; Minamino, T.; Asanuma, H.; Fujita, M.; Wakeno, M.; Myoishi, M.; Tsukamoto, O.; Okada, K.; Koyama, H.; Komamura, K.; Takashima, S.; Shinozaki, Y.; Mori, H.; Shiraga, M.; Kitakaze, M.; Hori, M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol., 2006, 48(1), 176-184.
[http://dx.doi.org/10.1016/j.jacc.2006.04.008] [PMID: 16814664]
[10]
Li, L.; Takemura, G.; Li, Y.; Miyata, S.; Esaki, M.; Okada, H.; Kanamori, H.; Khai, N.C.; Maruyama, R.; Ogino, A.; Minatoguchi, S.; Fujiwara, T.; Fujiwara, H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation, 2006, 113(4), 535-543.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.568402] [PMID: 6449733]
[11]
Prunier, F.; Pfister, O.; Hadri, L.; Liang, L.; Del Monte, F.; Liao, R.; Hajjar, R.J. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(1), H522-H529.
[http://dx.doi.org/10.1152/ajpheart.00357.2006] [PMID: 16997893]
[12]
Carić, T.; Derek, O.; Carić, D. Effect of erythropoietin in a patient with severe congestive heart failure--a case report. Coll. Antropol., 2008, 32(2), 641-643.
[PMID: 18756924]
[13]
Li, L.; Yang, G.D.; Duan, W.; Zhang, H.C. Mechanisms underlying protective effect of erythropoietin on acute decompensated congestive heart failure in mice. Zhongguo Xin Yao Zazhi, 2011, 20(7), 619-624.
[14]
Belonje, A.M.; Voors, A.A.; van Gilst, W.H.; Anker, S.D.; Slart, R.H.; Tio, R.A.; Zijlstra, F.; van Veldhuisen, D.J. HEBE III investigators. Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am. Heart J., 2008, 155(5), 817-822.
[http://dx.doi.org/10.1016/j.ahj.2007.12.036] [PMID: 18440327]
[15]
Smith, K.J.; Bleyer, A.J.; Little, W.C.; Sane, D.C. The cardiovascular effects of erythropoietin. Cardiovasc. Res., 2003, 59(3), 538-548.
[http://dx.doi.org/10.1016/S0008-6363(03)00468-1 ] [PMID: 14499855]
[16]
Westenbrink, B.D.; Lipsic, E.; van der Meer, P.; van der Harst, P.; Oeseburg, H.; Du Marchie Sarvaas, G.J.; Koster, J.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H.; Schoemaker, R.G. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J., 2007, 28(16), 2018-2027.
[http://dx.doi.org/10.1093/eurheartj/ehm177] [PMID: 17576662]
[17]
Parsa, C.J.; Kim, J.; Riel, R.U.; Pascal, L.S.; Thompson, R.B.; Petrofski, J.A.; Matsumoto, A.; Stamler, J.S.; Koch, W.J. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J. Biol. Chem., 2004, 279(20), 20655-20662.
[http://dx.doi.org/10.1074/jbc.M314099200] [PMID: 15020586]
[18]
Lipsic, E.; Schoemaker, R.G.; van der Meer, P.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H. Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J. Am. Coll. Cardiol., 2006, 48(11), 2161-2167.
[http://dx.doi.org/10.1016/j.jacc.2006.08.031] [PMID: 17161240]
[19]
Lipsic, E.; Westenbrink, B.D.; van der Meer, P.; van der Harst, P.; Voors, A.A.; van Veldhuisen, D.J.; Schoemaker, R.G.; van Gilst, W.H. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur. J. Heart Fail., 2008, 10(1), 22-29.
[http://dx.doi.org/10.1016/j.ejheart.2007.10.008] [PMID: 18077209]
[20]
van der Meer, P.; Groenveld, H.F.; Januzzi, J.L., Jr; van Veldhuisen, D.J. Erythropoietin treatment in patients with chronic heart failure: A meta-analysis. Heart, 2009, 95(16), 1309-1314.
[http://dx.doi.org/10.1136/hrt.2008.161091] [PMID: 19168472]
[21]
Li, X-J.; Wang, X-W.; Du, Y-J. Protective effects of erythropoietin on myocardial infarction in rats: The role of AMP-activated protein kinase signaling pathway. Am. J. Med. Sci., 2011, 342(2), 153-159.
[http://dx.doi.org/10.1097/MAJ.0b013e318210041d] [PMID: 21415704]
[22]
Mastromarino, V.; Volpe, M.; Musumeci, M.B.; Autore, C.; Conti, E. Erythropoietin and the heart: Facts and perspectives. Clin. Sci. (Lond.), 2011, 120(2), 51-63.
[http://dx.doi.org/10.1042/CS20100305] [PMID: 20929439]
[23]
Gobe, G.C.; Morais, C.; Vesey, D.A.; Johnson, D.W. Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J. Nephropathol., 2013, 2(3), 154-165.
[PMID: 24475445]
[24]
Zhang, X.; Tang, N.; Hadden, T.J.; Rishi, A.K. Akt, FoxO and regulation of apoptosis. Biochimica et Biophysica Acta (BBA)-. Mol. Cell Res., 2011, 1813(11), 1978-1986.
[25]
Moon, C.; Krawczyk, M.; Paik, D.; Lakatta, E.G.; Talan, M.I. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc. Drugs Ther., 2005, 19(4), 243-250.
[http://dx.doi.org/10.1007/s10557-005-3189-6] [PMID: 16187008]
[26]
Moon, C.; Krawczyk, M.; Paik, D.; Coleman, T.; Brines, M.; Juhaszova, M.; Sollott, S.J.; Lakatta, E.G.; Talan, M.I. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther., 2006, 316(3), 999-1005.
[http://dx.doi.org/10.1124/jpet.105.094854] [PMID: 16306273]
[27]
Angeli, F.S.; Amabile, N.; Burjonroppa, S.; Shapiro, M.; Bartlett, L.; Zhang, Y.; Virmani, R.; Chatterjee, K.; Boyle, A.; Grossman, W.; Yeghiazarians, Y. Prolonged therapy with erythropoietin is safe and prevents deterioration of left ventricular systolic function in a porcine model of myocardial infarction. J. Card. Fail., 2010, 16(7), 579-589.
[http://dx.doi.org/10.1016/j.cardfail.2010.02.008] [PMID: 20610234]
[28]
Shi, Y.; Rafiee, P.; Su, J.; Pritchard, K.A., Jr; Tweddell, J.S.; Baker, J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol., 2004, 99(3), 173-182.
[http://dx.doi.org/10.1007/s00395-004-0455-x] [PMID: 15088102]
[29]
van der Meer, P.; Lipsic, E.; Henning, R.H.; Boddeus, K.; van der Velden, J.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H.; Schoemaker, R.G. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol., 2005, 46(1), 125-133.
[http://dx.doi.org/10.1016/j.jacc.2005.03.044 PMID: 15992646]
[30]
Lipšic, E.; van der Meer, P.; Henning, R.H.; Suurmeijer, A.J.; Boddeus, K.M.; van Veldhuisen, D.J.; van Gilst, W.H.; Schoemaker, R.G. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol., 2004, 44(4), 473-479.
[http://dx.doi.org/10.1097/01.fjc.0000140209.04675.c3 ] [PMID: 15454856]
[31]
Prunier, F.; Pottier, P.; Clairand, R.; Mercier, A.; Hajjar, R.J.; Planchon, B.; Furber, A. Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect. Cardiology, 2009, 112(2), 129-134.
[http://dx.doi.org/10.1159/000142723] [PMID: 18596374]
[32]
Olivetti, G.; Quaini, F.; Sala, R.; Lagrasta, C.; Corradi, D.; Bonacina, E.; Gambert, S.R.; Cigola, E.; Anversa, P. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J. Mol. Cell. Cardiol., 1996, 28(9), 2005-2016.
[http://dx.doi.org/10.1006/jmcc.1996.0193] [PMID: 8899559]
[33]
Ruvinov, E.; Sharabani-Yosef, O.; Nagler, A.; Einbinder, T.; Feinberg, M.S.; Holbova, R.; Douvdevani, A.; Leor, J. Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. Fibrogenesis Tissue Repair, 2008, 1(1), 7.
[http://dx.doi.org/10.1186/1755-1536-1-7] [PMID: 19014419]
[34]
Cai, Z.; Manalo, D.J.; Wei, G.; Rodriguez, E.R.; Fox-Talbot, K.; Lu, H.; Zweier, J.L.; Semenza, G.L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation, 2003, 108(1), 79-85.
[http://dx.doi.org/10.1161/01.CIR.0000078635.89229.8A ] [PMID: 12796124]
[35]
Calvillo, L.; Latini, R.; Kajstura, J.; Leri, A.; Anversa, P.; Ghezzi, P.; Salio, M.; Cerami, A.; Brines, M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. USA,, 2003, 100(8), 4802-4806.
[http://dx.doi.org/10.1073/pnas.0630444100 ] [PMID: 12663857]
[36]
Brines, M.L.; Ghezzi, P.; Keenan, S.; Agnello, D.; de Lanerolle, N.C.; Cerami, C.; Itri, L.M.; Cerami, A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA,, 2000, 97(19), 10526-10531.
[http://dx.doi.org/10.1073/pnas.97.19.10526 ] [PMID: 10984541]
[37]
Jaquet, K.; Krause, K.; Tawakol-Khodai, M.; Geidel, S.; Kuck, K-H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res., 2002, 64(2), 326-333.
[http://dx.doi.org/10.1006/mvre.2002.2426] [PMID: 12204656]
[38]
Shingo, T.; Sorokan, S.T.; Shimazaki, T.; Weiss, S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci., 2001, 21(24), 9733-9743.
[http://dx.doi.org/10.1523/JNEUROSCI.21-24-09733.2001 ] [PMID: 11739582]
[39]
Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 2003, 102(4), 1340-1346.
[http://dx.doi.org/10.1182/blood-2003-01-0223] [PMID: 12702503]
[40]
Moon, C.; Krawczyk, M.; Ahn, D.; Ahmet, I.; Paik, D.; Lakatta, E.G.; Talan, M.I. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA, 2003, 100(20), 11612-11617.
[http://dx.doi.org/10.1073/pnas.1930406100] [PMID: 14500913]
[41]
Zhao, W.; Lu, L.; Chen, S.S.; Sun, Y. Temporal and spatial characteristics of apoptosis in the infarcted rat heart. Biochem. Biophys. Res. Commun., 2004, 325(2), 605-611.
[http://dx.doi.org/10.1016/j.bbrc.2004.10.064 ] [PMID: 15530436]
[42]
Feng, Q.Z.; Li, T.D.; Wei, L.X.; Qiao, X.; Yi, J.; Wang, L.; Yang, T.S. Tempero-spatial dissociation between the expression of Fas and apoptosis after coronary occlusion. MP. Mol. Pathol., 2003, 56(6), 362-367.
[http://dx.doi.org/10.1136/mp.56.6.362 PMID: 14645700]
[43]
Frantz, S.; Vallabhapurapu, D.; Tillmanns, J.; Brousos, N.; Wagner, H.; Henig, K.; Ertl, G.; Müller, A.M.; Bauersachs, J. Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction. Eur. J. Heart Fail., 2008, 10(2), 119-124.
[http://dx.doi.org/10.1016/j.ejheart.2007.11.009 ] [PMID: 18279767]
[44]
Dawn, B.; Guo, Y.; Rezazadeh, A.; Huang, Y.; Stein, A.B.; Hunt, G.; Tiwari, S.; Varma, J.; Gu, Y.; Prabhu, S.D.; Kajstura, J.; Anversa, P.; Ildstad, S.T.; Bolli, R. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ. Res., 2006, 98(8), 1098-1105.
[http://dx.doi.org/10.1161/01.RES.0000218454.76784.66 ] [PMID: 16556872]
[45]
Piepoli, M.F.; Vallisa, D.; Arbasi, M.; Cavanna, L.; Cerri, L.; Mori, M.; Passerini, F.; Tommasi, L.; Rossi, A.; Capucci, A. Cardiac Study Group. Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study). Eur. J. Heart Fail., 2010, 12(2), 172-180.
[http://dx.doi.org/10.1093/eurjhf/hfp183] [PMID: 20042424]
[46]
Yeghiazarians, Y.; Zhang, Y.; Prasad, M.; Shih, H.; Saini, S.A.; Takagawa, J.; Sievers, R.E.; Wong, M.L.; Kapasi, N.K.; Mirsky, R.; Koskenvuo, J.; Minasi, P.; Ye, J.; Viswanathan, M.N.; Angeli, F.S.; Boyle, A.J.; Springer, M.L.; Grossman, W. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Mol. Ther., 2009, 17(7), 1250-1256.
[http://dx.doi.org/10.1038/mt.2009.85] [PMID: 19384293]
[47]
Angeli, F.S.; Amabile, N.; Shapiro, M.; Mirsky, R.; Bartlett, L.; Zhang, Y.; Virmani, R.; Chatterjee, K.; Boyle, A.; Grossman, W.; Yeghiazarians, Y. Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction. Cardiovasc. Drugs Ther., 2010, 24(5-6), 409-420.
[http://dx.doi.org/10.1007/s10557-010-6263-7 ] [PMID: 20809214]
[48]
Yeghiazarians, Y.; Khan, M.; Angeli, F.S.; Zhang, Y.; Jahn, S.; Prasad, M.; Mirsky, R.; Shih, H.; Minasi, P.; Boyle, A.; Grossman, W. Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J. Card. Fail., 2010, 16(8), 669-678.
[http://dx.doi.org/10.1016/j.cardfail.2010.03.008 ] [PMID: 20670846]
[49]
Olea, F.D.; Vera Janavel, G.; De Lorenzi, A.; Cuniberti, L.; Yannarelli, G.; Cabeza Meckert, P.; Cearras, M.; Laguens, R.; Crottogini, A. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J. Cardiovasc. Pharmacol., 2006, 47(6), 736-741.
[http://dx.doi.org/10.1097/01.fjc.0000211766.59636.0d ] [PMID: 16810073]
[50]
van der Meer, P.; Lipsic, E.; Henning, R.H.; de Boer, R.A.; Suurmeijer, A.J.; van Veldhuisen, D.J.; van Gilst, W.H. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart Fail., 2004, 6(7), 853-859.
[http://dx.doi.org/10.1016/j.ejheart.2004.03.012 ] [PMID: 15556046]
[51]
Dimmeler, S.; Zeiher, A.M.; Schneider, M.D. Unchain my heart: The scientific foundations of cardiac repair. J. Clin. Invest., 2005, 115(3), 572-583.
[http://dx.doi.org/10.1172/JCI200524283] [PMID: 15765139]
[52]
Murry, C.E.; Soonpaa, M.H.; Reinecke, H.; Nakajima, H.; Nakajima, H.O.; Rubart, M.; Pasumarthi, K.B.; Virag, J.I.; Bartelmez, S.H.; Poppa, V.; Bradford, G.; Dowell, J.D.; Williams, D.A.; Field, L.J. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature, 2004, 428(6983), 664-668.
[http://dx.doi.org/10.1038/nature02446] [PMID: 15034593]
[53]
Multilineage differentiation of transplanted allogenic mesenchymal stem cells injected in a porcine model of recent myocardial infarction improves left ventricular function. Makkar, R.; Price, M.; Lill, M.; Takizawa, K.; Frantzen, M.; Fishbein, M.; Eds, Circulation; Lippincott Williams & Wilkins: 530 Walnut St., Philadelphia, PA 19106-3621 USA, 2002.
[54]
Lipsic, E. Protective effects of erythropoietin in cardiac ischemia from bench to bedside. J. Am. Coll. Cardiol., 2001, 37, 1775-1780.
[PMID: 17161240]
[55]
Hamed, S.; Barshack, I.; Luboshits, G.; Wexler, D.; Deutsch, V.; Keren, G.; George, J. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur. Heart J., 2006, 27(15), 1876-1883.
[http://dx.doi.org/10.1093/eurheartj/ehl044] [PMID: 16731534]
[56]
Lipšic, E.; van der Meer, P.; Voors, A.A.; Westenbrink, B.D.; van den Heuvel, A.F.; de Boer, H.C.; van Zonneveld, A.J.; Schoemaker, R.G.; van Gilst, W.H.; Zijlstra, F.; van Veldhuisen, D.J. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc. Drugs Ther., 2006, 20(2), 135-141.
[http://dx.doi.org/10.1007/s10557-006-7680-5 ] [PMID: 16761193]
[57]
Freimark, D.; Matetzky, S.; Hod, H.; Chouragui, P.; Kaplinsky, E.; Rabinowitz, B. High early peak creatine kinase after thrombolysis in patients with acute anterior infarction predicts poor left ventricular function. Cardiology, 1995, 86(5), 411-416.
[http://dx.doi.org/10.1159/000176912] [PMID: 7585745]
[58]
Panteghini, M.; Cuccia, C.; Bonetti, G.; Giubbini, R.; Pagani, F.; Bonini, E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin. Chem., 2002, 48(9), 1432-1436.
[http://dx.doi.org/10.1093/clinchem/48.9.1432 ] [PMID: 12194919]
[59]
van der Laarse, A.; Kerkhof, P.L.; Vermeer, F.; Serruys, P.W.; Hermens, W.T.; Verheugt, F.W.; Bär, F.W.; Krauss, X.H.; van der Wall, E.E.; Simoons, M.L. Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am. J. Cardiol., 1988, 61(1), 1-7.
[http://dx.doi.org/10.1016/0002-9149(88)91294-5 ] [PMID: 2962483]
[60]
Ozawa, T.; Toba, K.; Suzuki, H.; Kato, K.; Iso, Y.; Akutsu, Y.; Kobayashi, Y.; Takeyama, Y.; Kobayashi, N.; Yoshimura, N.; Akazawa, K.; Aizawa, Y. EPO/AMI-I Pilot Study Researchers. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction-randomized controlled pilot trial of EPO/AMI-1 study. Circ. J., 2010, 74(7), 1415-1423.
[http://dx.doi.org/10.1253/circj.CJ-10-0109 ] [PMID: 20501957]

Rights & Permissions Print Cite
Article Metrics
42
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy